Positive response to neoadjuvant cyclophosphamide and doxorubicin in topoisomerase II nonamplified/HER2/neu negative/polysomy 17 absent breast cancer patients

Figures & data

Figure 1 TOP2A amplified cells.

Table 1 Descriptors of patients tested for TOP2A (n = 34)

Variable	N (%)
Age in years
Range	29–66
Mean	46.47
TNM stage
II	11 (32%)
III	19 (56%)
IV	4 (12%)
Lymph node status
Negative	8 (24%)
Positive	26 (76%)
Clinical tumor size, cm
Range	1.6–11.0
Mean	6.13
Histologic type
Ductal	27 (79%)
Lobular	3 (9%)
Other	4 (12%)
Histologic grade
Intermediate	2 (9%)
High	30 (88%)
Nuclear grade
Low to intermediate	9 (26%)
Intermediate	1 (3%)
High	24 (71%)
ER = positive	17 (50%)
PR = positive	11 (32%)
Her2 = positive	9 (27%)
TOP2A
Normal	33 (97%)
Amplified	1 (3%)
PS17
Not present	32 (94%)
Present	2 (6%)
Number of treatment cycles
Weekly	1 (3%)
<4	2 (6%)
4	24 (71%)
5	3 (9%)
6	4 (12%)

Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TOP2A, topoisomerase II alpha; PS17, polysomy 17.

Table 2 Summary of response to treatment by HER2 negative, TOP2A absent, and polysomy 17 absent status

HER2 status	TOP2A status	Polysomy 17 status	N	pCR, %	PR, %	NR, %
–	Nonamplified	–	33	12	64	24
–	Nonamplified	Absent	31	13	61	26
Negative	Nonamplified	–	24	8	63	29
Negative	Nonamplified	Absent	23	9	61	30

Abbreviations: HER2, human epidermal growth factor receptor 2; TOP2A, topoisomerase II alpha, pCR, pathological complete response; PR, partial response; NR, nonresponse.

Figure 2 Diagram of neoadjuvant treatment study subjects.

Table 3 Response to treatment by hormone receptor and HER2 status (n = 34)a

Hormone receptor status	HER2 status	N	pCR, %	PR, %	NR, %
Negative	Negative	10	20	60	20
Positive	Negative	15	0	67	33
Negative	Positive	6	33	67	0
Positive	Positive	3	0	67	33
Total		34	12	65	24

a Pearson χ² = 7.32, 6 degrees of freedom, P = 0.293 (3 zero cells).

Abbreviations: HER2, human epidermal growth factor receptor 2; pCR, pathological complete response; PR, partial response; NR, nonresponse.